Company Overview

Company name: CannPal Animal (ASX: CP1)
Description: CannPal Animal Therapeutics Ltd is an animal-focused pharmaceutical company. It is engaged in developing standardized and dosage controlled, regulatory approved pharmaceuticals, derived from the cannabis plant. The company is intended for developing cannabinoid-based therapeutics with an initial focus on cats, dogs, and horses.
Year founded:
Parent company:
Industry: Healthcare | Group: | Code:
City: Sydney
State: New South Wales
Country: Australia

Financial Highlights

Start up capital raised (USD Million):
Business status: Generating Revenue/Not Profitable
Ownership: Publicly Held
Exchange: ASX
Ticker: CP1
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Enterprise value: 5,34
Earnings before interest, tax, depreciation and amortization (EBITDA):
Fiscal period: TTM 1Q2021
Financing Status:
Number of active investors:
Profile last updated:
Last known valuation: 12,52
Last known valuation date: 16-nov-2020